A newly published paper in PNAS details a research breakthrough that provides a promising starting point for scientists to create drugs that can cure C. diff—a virulent health care-associated ...

Researchers from the University of Maryland School of Medicine and their colleagues have identified the structure of the most lethal toxin produced by certain strains of Clostridium difficile bacteria ...

Affecting roughly half a million Americans each year, bacterial infections caused by Clostridioides difficile—commonly known as C. diff—are a serious and persistent problem for patients and hospitals ...

A novel combination of multiple advanced molecular imaging techniques has led to the discovery of two molecular structures, which could provide a therapeutic target for C. diff infections. “The most ...

The presence of antigen-specific and neutralizing antibodies was not associated with Clostridioides difficile infection symptoms, severity, therapy approach, treatment response, or recurrences in a ...

A study published by PNAS explains breakthrough research around designing drugs that target C. diff bacterial infections that result in 15,000 deaths in the U.S. annually. The bacterium is potentially ...

A new imaging approach used microscopic glowing tags to reveal gene activity in individual C. diff cells in gut tissue samples from infected mice. Here, a resulting image shows a round cross-section ...

Clostridium difficile infection (CDI) is a common hospital-acquired infection that is associated with a high clinical and economic burden. Because of this management of CDI is quickly becoming a part ...

A toxoid vaccine candidate against Clostridioides difficile failed to reduce the incidence of infection in at-risk adults ages 50 and older, according to results of the phase III CLOVER trial. Of ...